Findings of lower proBNP levels, CS development risk and/or improved cardiac function in the treatment arms would support the hypothesis that subclinical signs of CS can be routinely targeted and that this may be of benefit in an at-risk population. This evidence concerns the gene NPPB and Cowden syndrome 1.